BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of ...

BD. (BDX), a global medical technology company, and Biosero, a developer of laboratory automation solutions, Thursday announced that ...

Franklin Lakes, New Jersey Saturday, January 25, 2025, 10:00 Hrs [IST] ...

BD, a global medical technology company, and Biosero, a developer of laboratory automation solutions, have joined forces to ...

Dr. Christopher Flowers discusses MRD testing in cancer care, why this is an important concept to understand and how it ...

Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients ...

Trapped immune cells laden with microplastics starve the brain of oxygen—mouse study links vascular blockages to memory loss and motor deficits, with lingering risks even after symptoms fade.

Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...

To support physicians in treating cancer patients, oncology laboratories can benefit from adopting end-to-end automation of flow cytometry workflows. Rapid advances in automation are improving ...

Frizzled (FZD) proteins are the principal receptors of the Wnt signaling pathway. However, whether Wnt ligands induce FZD endocytosis and degradation remains elusive. The transmembrane E3 ubiquitin ...

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic ...